retatrutide vs tirzepatide efficacy UK (2026) Research Guide 28.7% Weight Loss in New

Both medications carry a black box warning for this

Retatrutide appears to: Target deep abdominal fat Reduce waist circumference more significantly Improve metabolic syndrome components Safety and Tolerability Side Effects: Similar to GLP-1 Agonists Nausea Vomiting Diarrhea or constipation Fatigue in early weeks Mitigation strategy: Start at low doses and titrate slowly Consider antiemetics in sensitive patients While retatrutides triple action raises theoretical concerns, early data show comparable tolerability to tirzepatide , with no increase in severe adverse events

What the research shows about tirzepatide and lean mass A systematic review published in 2025 examining tirzepatide effects on skeletal muscle mass found that lean tissue loss accounts for 20% to 34% of total weight lost during treatment

Pivotal Phase 3 trials Trial SURMOUNT-1 (NEJM 2022) Population 2,539 adults, obesity, no diabetes

Both tirzepatide and semaglutide are FDA-approved, have support from more long-term data, and are already used in real-life settings

Independent purity verification is particularly critical for dual-receptor agonist peptides where structural integrity determines receptor binding specificity and clinical activity